Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
SAN DIEGO and TORONTO, Jan. 02, 2018 -- Aptose Biosciences Inc. (Nasdaq:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming Biotech ShowcaseTM 2018 Conference on Monday, January 8th, 2018 at 11:00 a.m. PST in San Francisco, CA.
Conference Presentation Details:
| Date: | Monday, January 8, 2018 | ||||||||
| Time: | 11:00 a.m. PST | ||||||||
| Location: | Track Yosemite - C (Ballroom Level) | ||||||||
| Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102 | |||||||||
| Webcast: | https://event.webcasts.com/starthere.jsp?ei=1176654&tp_key=e58ab4bdea | ||||||||
The audio webcast will be archived shortly after the live event and will be available through the Aptose website at www.aptose.com.
The Company will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.
To schedule a meeting with Aptose, investors can register on the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at [email protected].
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
[email protected]
LifeSci Advisors, LLC
Dan Ferry
Managing Director
617-535-7746
[email protected]
